Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes (NCT06699979) | Clinical Trial Compass
RecruitingNot Applicable
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
China300 participantsStarted 2024-08-29
Plain-language summary
The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on. The main questions it aims to answer are:
* What are the differences in pathogenesis of non-small cell lung cancer with different phenotypes explored by multi-omics?
* Whether differential genes lead to potential prognostic models and therapeutic targets? Participants will be followed up after surgery to answer prognosis: whether they have recurred, and the time to recurrence.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
✓. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);
✓. Good compliance, family members agree to cooperate to receive survival follow-up;
✓. Understand and voluntarily sign the informed consent.
Exclusion criteria
✕. A history of previous or co-existing malignant tumors;
✕. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
✕. Refusal to participate in the study.
✕. Male or female patients:18-75 years old;
What they're measuring
1
Immune repertoire sequencing
Timeframe: From enrollment to the end of surgery for 3 years
2
DNA methylome sequencing
Timeframe: From enrollment to the end of surgery for 3 years
3
RNA sequencing
Timeframe: From enrollment to the end of surgery for 3 years